arrow
S

Seema Rao Gorla

astellas pharma
H指数:13
被引数:1,533

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma

EV-103剂量递增/队列A:恩沃利单抗 vedotin 联合帕博利珠单抗治疗既往未治疗的局部晚期/转移性尿路上皮癌的5年随访

2026-05-190
OAAI
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma
2026-01-210
OAAI
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302研究的探索性亚组分析:一项评估恩诺单抗(enfortumab vedotin)联合帕博利珠单抗(pembrolizumab)与化疗对比治疗既往未治疗的局部晚期或转移性尿路上皮癌的III期全球研究

2025-08-110
OAAI
Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

恩沃利单抗(enfortumab vedotin)在铂类和PD-1/PD-L1抑制剂方案治疗后疾病进展的晚期非小细胞肺癌患者中的疗效:国际多中心EV-202期2研究

2025-07-090
OA
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆

恩诺单抗维多汀联合帕博利珠单抗治疗未经治疗的局部晚期或转移性尿路上皮癌:III期EV-302/KEYNOTE-A39试验的中位2.5年随访结果☆

2025-06-010
PREAI
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Enfortumab Vedotin和Pembrolizumab在未经治疗的晚期尿路上皮癌中的应用

2024-03-07153
PRE
EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
2023-11-012
PRE
EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
2023-10-0191
OA